Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Short-term Investments: 2020-2025

Historic Short-term Investments for Tarsus Pharmaceuticals (TARS) over the last 4 years, with Sep 2025 value amounting to $289.1 million.

  • Tarsus Pharmaceuticals' Short-term Investments rose 105.42% to $289.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $289.1 million, marking a year-over-year increase of 105.42%. This contributed to the annual value of $196.6 million for FY2024, which is 7778.04% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Short-term Investments stood at $289.1 million, which was up 1.62% from $284.5 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' 5-year Short-term Investments high stood at $289.1 million for Q3 2025, and its period low was $20,000 during Q1 2021.
  • Its 3-year average for Short-term Investments is $147.2 million, with a median of $140.7 million in 2024.
  • The largest annual percentage gain for Tarsus Pharmaceuticals' Short-term Investments in the last 5 years was 46,368.04% (2023), contrasted with its biggest fall of 98.28% (2023).
  • Quarterly analysis of 5 years shows Tarsus Pharmaceuticals' Short-term Investments stood at $483,000 in 2021, then spiked by 29,996.48% to $145.4 million in 2022, then slumped by 98.28% to $2.5 million in 2023, then surged by 7,778.04% to $196.6 million in 2024, then surged by 105.42% to $289.1 million in 2025.
  • Its Short-term Investments was $289.1 million in Q3 2025, compared to $284.5 million in Q2 2025 and $232.1 million in Q1 2025.